Skip to content
Apogee
-
AbbVie solidifies immunology dominance with US$10.9B cash acquisition of Apogee
The acquisition ranks among AbbVie’s largest transactions in recent years and reflects the company’s strategy to expand its next-generation immunology medicines as competition intensifies across the sector.
-
Apogee Therapeutics secures US$1.3B Blackstone deal for phase 3 eczema drug
Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.